GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patientâ€™s immune systemâ€™s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI

Market Cap	17.01M 14.88M 13.66M 12.75M 24.16M 1.62B 24.52M 164M 63.78M 795M 63.88M 62.49M 2.75B	P/E 2026 *	-1.39x	P/E 2027 *	-1.75x
Enterprise Value	17.01M 14.88M 13.66M 12.75M 24.16M 1.62B 24.52M 164M 63.78M 795M 63.88M 62.49M 2.75B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	78.38%	Yield 2026 *	-	Yield 2027 *	-

06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI
06-01	GT Biopharma, Inc. Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	CI
05-29	GT Biopharma Advances Three Trike Drug Candidates into Human Trials	CI
05-15	GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors	RE
05-14	Gt Biopharma Inc Announces First Patient Dosed in Phase 1 Trial of Gtb-5550, A B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors	CI
04-07	GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota	CI
03-02	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-02	GT Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-03	GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3	CI
02-03	GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors	RE
01-15	GT Biopharma, Inc. Announces IND Submission for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for B7-H3 Expressing Solid Tumor Cancers	CI

05/01/23	EF Hutton Starts GT Biopharma at Hold With $2 Price Target	MT
13/09/22	HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	MT
12/08/22	Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	MT
24/01/22	B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
24/06/21	GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	MT

06-30	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
06-12	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ
06-08	Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet	AQ
06-01	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	AQ
05-15	GT Biopharma Reports First Quarter 2026 Financial Results	AQ

Oxis International Stock Euronext Paris

Stocks

US6918294025

Biotechnology & Medical Research

Valuation: Oxis International

Latest news : Oxis International

Analysts' recommendations: Oxis International

Press Releases: Oxis International

News in other languages: Oxis International

Managers and Directors: Oxis International

Bio Therapeutic Drugs

Financials

Company Profile

30/04/24	Caterpillar deja París, el cacao está menos caliente
30/04/24	Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud

Manager	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	64	02/03/2022
Alan Urban DFI	Director of Finance/CFO	57	03/06/2024

Director	Title	Age	Since
Michael Breen CHM	Chairman	64	15/12/2021
Charles Casamento BRD	Director/Board Member	81	01/05/2023
Hilary Kramer BRD	Director/Board Member	62	07/05/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	19.69B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	16.22B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	14.84B
Average	+2.87%	+8.57%	+54.64%	+148.04%	27.28B
Weighted average by Cap.	+2.46%	+6.47%	+59.06%	+137.71%

	2026 *	2027 *
Net sales	-	-
Net income	-12.27M -10.73M -9.85M -9.19M -17.42M -1.17B -17.68M -118M -45.99M -574M -46.06M -45.06M -1.98B	-12.7M -11.11M -10.19M -9.52M -18.03M -1.21B -18.3M -122M -47.6M -594M -47.68M -46.64M -2.05B
Net Debt	-	-

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-